Susan Shapiro

Susan Shapiro is an experienced and award-winning journalist who has been in the industry for many years. She currently serves as the solo anchor of News 8 at Noon and health reporter on the News 8 On Your Side Team at WGAL. Susan started her career at WGAL in 1981 as a reporter, later anchoring morning and weekend news reports. Before joining WGAL, she worked as an anchor and reporter at WTAJ-TV in Altoona, Pennsylvania, and as a research assistant for Philadelphia Magazine. Throughout her career, Susan has received multiple awards for her reporting work including a 2005 Mid-Atlantic Region Emmy for individual achievement in feature reporting and a 1992 Emmy Award for spot news. She is also on the Board of Governors of the Philadelphia Regional Chapter of the National Academy of Television Arts and Sciences. Susan graduated with a bachelor's degree in journalism from Pennsylvania State University and studied British mass media at Manchester University in England.

77%

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

75%

Examples:

  • Susan has received numerous awards and honors for her reporting, including a 2005 Mid-Atlantic Region Emmy for individual achievement for feature reporting and a 1992 Emmy Award for spot news.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

50%

Examples:

  • The deception in the article is that Susan uses a quote from a diabetic patient which implies that the medication is essential for their health when it's not necessarily true.

Recent Articles

GLP-1 Drug Shortage: Diabetics Struggle to Obtain Necessary Dosages for Type 2 Diabetes Management

GLP-1 Drug Shortage: Diabetics Struggle to Obtain Necessary Dosages for Type 2 Diabetes Management

Broke On: Friday, 19 July 2024 A critical shortage of GLP-1 receptor agonist drugs, including Trulicity, leaves diabetics like Bob Dohman unable to obtain necessary dosages. The scarcity affects healthcare providers as they scramble for alternatives and secure limited supplies. Experts debate prioritizing patients for coverage and discuss strategies to address this pressing issue. Meanwhile, the choice between weight loss drugs Mounjaro and Ozempic should not be based on a single study.